5 years of imatinib treatment for high-risk gastrointestinal stromal tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the efficacy and safety of administering adjuvant imatinib for five years to patients with high-risk gastrointestinal stromal tumors (GISTs) following surgical resection. It focuses on patients with tumor rupture or those with large tumors and a high mitotic index. The study aims to improve recurrence-free survival rates by evaluating the long-term effects of imatinib, a tyrosine-kinase inhibitor, on these patients. The research builds on previous findings that suggest adjuvant imatinib can enhance outcomes for GIST patients at high risk of recurrence.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 20 years or older, at the time of acquisition of informed consent
2. Histologically confirmed GIST with CD117(+), DOG-1(+), or mutation in KIT or PDGFRα gene
3. (1) Completely resected localized GIST (R0 resection) within 12 weeks prior to the start of the adjuvant imatinib.

(2) After complete resection(R0 resection), High risk GIST according to Modified NIH criteria and ongoing adjuvant imatinib treatment.

4\) High risk GIST according to Modified NIH criteria,

1. Tumor rupture according to Nishida classification or
2. tumor size \>10cm and mitosis \>10/50 HPF 5) Eastern Cooperative Oncology Group (ECOG) performance status 0 \~ 2 6) Adequate bone marrow, hepatic, renal, and other organ functions, before adjuvant imatinib treatment

   * Neutrophil \>1,500/mm3
   * Platelet \> 100,000/mm3
   * Hemoglobin \>8.0 g/dL
   * Total bilirubin \< 1.5 x upper limit of normal (ULN)
   * AST/ALT \< 2.5 x ULN
   * Creatinine \<1.5 x ULN 7) Provision of a signed written informed consent

Exclusion Criteria:

1. Women of child-bearing potential who are pregnant or breast feeding
2. Women or men who are not willing to use effective contraception entering the study period or until at least 3 months after the last study drug administration.
3. If any of the following applies within ≤ 6 months prior to starting study enrollment : Myocardial Infarction, severe instable angina, coronary/peripheral bypass, NYHA class III or IV congestive heart failure, stroke or transient ischemic attack, treatment required severe arrhythmia.
4. Uncontrolled infection
5. Acute and chronic liver disease and all chronic liver impairment.(But Patients with stable chronic hepatitis B are eligible)
6. Patients who had reduced the dose of imatinib to less than 300 mg/day due to toxicity.
7. Acute, or chronic medical or psychiatric condition or laboratory abnormality such as active uncontrolled infection that difficult to study participation in the judgment of the investigator
8. Known diagnosis of HIV infection (HIV testing is not mandatory).
9. History of another primary malignancy that is currently clinically significant or currently requires active intervention.
10. Alcohol or substance abuse disorder.
11. The patients with PDGFRα D842V mutation

Where it's running

• Asan Medical Center, University of Ulsan College of Medicine
  Seoul, Seoul, South Korea Recruiting

Study contacts

• Study coordinator: Ryu Min-Hee, MD, PhD
• Email: miniryu@amc.seoul.kr
• Phone: 82-2-3010-5936

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Imatinib plus fampridine before surgery for KIT exon 11 gastrointestinal stromal tumor

  This trial tests whether adding fampridine to standard imatinib before surgery is safe and helps shrink KIT exon 11 mutant GIST tumors in adults.

  Recruiting Phase 1 University of California, San Diego · La Jolla, California · NCT07171203

• Oral Liporaxel (paclitaxel) treatment for gastrointestinal stromal tumors

  This study will test whether taking oral Liporaxel (a form of paclitaxel) can help people with advanced GIST who stopped responding to imatinib, sunitinib, and regorafenib and whose tumors have low P‑glycoprotein levels.

  Recruiting Phase 2 Asan Medical Center · Seoul, Songpagu · NCT06326346

• Combination of rivoceranib and paclitaxel for advanced gastrointestinal stromal tumors

  This study is testing if a new combination of two drugs, rivoceranib and paclitaxel, can help adults with advanced gastrointestinal stromal tumors that haven't improved with standard treatments.

  Recruiting Phase 2 Asan Medical Center · Seoul, Seoul · NCT05905887

• Using imatinib to improve outcomes in gastrointestinal stromal tumors

  This study is testing if monitoring imatinib levels can help improve the quality of life for people with gastrointestinal stromal tumors while reducing side effects.

  Recruiting Phase 2 University of Kentucky · Lexington, Kentucky · NCT05493215

• Velzatinib for advanced GIST after multiple prior TKIs

  This study tests velzatinib to see if it can shrink or slow tumors in people with metastatic or unresectable GIST who have progressed on or could not tolerate standard therapies.

  Recruiting at 3 sites Phase 2 GlaxoSmithKline · Fukuoka and 2 other locations · NCT07689201

• DCC-2618 in GIST after at least 3 prior treatments

  This trial tests whether DCC-2618 is safe in people with advanced GIST who have already tried at least three other treatments.

  Recruiting at 2 sites Phase 1 Ono Pharmaceutical Co., Ltd. · Kashiwa, Chiba and 1 other locations · NCT07618377

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.